VRCI NEWS OUT
NEWS RELEASE VERDE SCIENCE PURSUING DEVELOPMENT OF PROMISING POINT-OF-CARE EBOLA SCREENING TEST Richmond, BC, Nov 10, 2014.
Date : 11/10/2014 @ 9:00AM
Source : InvestorsHub NewsWire
Stock : Verde Science, Inc. (PC) (VRCI)
Quote : 0.0061 0.0 (0.00%) @ 8:08AM
NEWS RELEASE VERDE SCIENCE PURSUING DEVELOPMENT OF PROMISING POINT-OF-CARE EBOLA SCREENING TEST Richmond, BC, Nov 10, 2014.
Print
Alert
VERDE SCIENCE PURSUING DEVELOPMENT OF PROMISING POINT-OF-CARE EBOLA SCREENING TEST
Richmond, BC, Nov 10, 2014. (OTCPK: VRCI) Verde Science, Inc., a Medical Research and Development Company focused on novel effective treatments for emerging and contemporary health issues, is pleased to announce that it is working with three new members of its R&D team in Canada and India to develop an easily administered point-of-care test for screening for Ebola and other closely related viruses. Following basic research Verde expects to develop a point-of-care testing kit that will enable health care practitioners to effectively screen for Ebola sometime in 2015.
According to Manit Patel, Verde Science Chief Technology Officer, “A shortage of specialized labs capable of handling potentially infected blood samples has made it difficult to track the Ebola outbreak. Our research is focused on developing a panel of tests to enable 1) simple point of care detection that will not require samples to be transported to specialized labs, and 2) molecular characterization of the detected viruses to allow differentiation of closely related viruses and identification of specific strains. Early detection and characterization of the pathogen is critical to containment of any infection.”
In line with its over arching vision, Verde Science’s current pipeline of research includes the isolation of active compounds from the marijuana plant for the treatment of specific medical conditions through pharmaceutical dosage formulations and diagnostic screening kits. Harp Sangha, Verde’s CEO stated, “This new development demonstrates the effectiveness of our model. By creating alliances with brilliant scientists and medical product developers world-wide, incorporating them into our overarching R&D structure, and applying professional administrative and financing techniques, we will be able to bring important medical breakthroughs to market in an expedited and cost-effective manner. We are in the process of screening capital raising opportunities for this and other projects and we are confident of our ability to fund our research under very acceptable terms.”
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a public company trading under the symbol OTCPK: VRCI. The Company is focused on Medical Research and Development, which includes medical marijuana research and the development of effective treatments for emerging and contemporary health issues that have been inadequately addressed.
Safe Harbor Statements?Certain information contained in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates", "intends" or "believes", or that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur", or "be achieved". Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
